Medical content governance is the system that decides who owns each clinical claim your company publishes, what evidence supports it, who must approve it, and when it gets rechecked or retired. If your product, website, sales decks, patient materials or AI outputs say anything about health, you already have a content governance program. The only question is whether it is written down or accidental.
This guide is for healthcare SaaS founders, digital health executives and investors who want a working model, not a theory. It covers what the term means, the roles and workflow that hold up under scrutiny, the U.S. rules that matter, and how to handle AI-assisted content.
TL;DR
- Medical content governance assigns a named owner, an evidence record, an approval path and an expiry date to every clinical claim you publish.
- It is not clinical governance (care quality) or AI governance (tool oversight), though it overlaps with both.
- Route review by risk, freeze the approved version, and keep an audit trail of who changed what and why.
- Compliance sets the legal boundary. Governance is the daily operating layer that keeps your team inside it.
- A small company can stand up a working program in 90 days with a physician leader, often fractional, accountable for clinical accuracy.
Table of Contents
- What medical content governance actually means
- Why healthtech companies need it
- Who does what: roles in the content chain
- A review and approval workflow that holds up
- Records: what an auditor or acquirer will ask for
- U.S. rules your program has to respect
- AI-assisted content: the new risk surface
- Our perspective: where programs fail
- A 90-day plan to stand up the program
- How we help
- FAQ
- Sources
What medical content governance actually means
The phrase gets used for three different things, and mixing them causes confusion.
Content governance in general is the system of processes, templates and guidelines that connects content strategy to day-to-day production. The U.S. Office of Disease Prevention and Health Promotion describes a content governance plan as a source of clarity and transparency that promotes consistency, makes teams more efficient and supports digital health literacy and usability.
Medical content governance applies that system to anything with clinical meaning: product copy, in-app guidance, patient education, clinical white papers, sales claims, investor materials and support scripts. The unit of control is the claim, not the page.
Clinical governance is a different object. It is the framework through which a care organization is accountable for the quality of care it delivers. We cover the operating side of that in our clinical governance framework for companies without a full-time CMO.
AI governance is different again. Duke-Margolis defines health-system AI governance as reviewing and evaluating individual AI tools for safe, responsible, fair and effective use with the organization's own patient population. Its object is the tool. Ours is the content.
A quick way to separate them:
| Discipline | What it governs | Typical owner |
|---|---|---|
| Clinical governance | Quality and safety of care delivery | Chief medical officer, quality committee |
| AI governance | Selection, monitoring and retirement of AI tools | AI oversight committee |
| Data governance | Data quality, access, lineage | Data or compliance lead |
| Medical content governance | Accuracy, evidence, approval and currency of clinical claims | Physician leader plus content owner |
The four share people and records. They do not share a purpose, and a company that treats one as a substitute for another leaves gaps.
Why healthtech companies need it
Three pressures push this from nice-to-have to necessary.
Regulatory exposure. Content that describes what a product does can be treated as a claim. In life sciences, governance is used to reduce regulatory risk and reputational damage, avoid launch delays and keep content consistent across its lifecycle. Digital health companies face a different mix of rules, but the logic carries over.
Buyer and investor diligence. Health system buyers ask who clinically reviewed your claims. Investors and acquirers ask the same during diligence. If the honest answer is "the founder, once, in 2023," that is a finding. Our healthcare SaaS due diligence guide shows how these gaps surface in M&A.
Speed. Without governance, every claim triggers a debate. With it, routine content moves through a known path and only high-risk items need senior attention. Governance done well is what lets a small team publish faster, not slower.
One distinction is worth holding onto. Compliance identifies the external legal boundaries. Governance is the internal operating layer that keeps daily decisions inside them. You need both, and governance is the one you can build this quarter.
Who does what: roles in the content chain
Every piece of medical content passes through five jobs, even if one person does several of them.
- Creator. Writes the draft: a product marketer, medical writer, clinician or engineer.
- Clinical reviewer. A licensed clinician whose expertise matches the topic.
- Regulatory or compliance reviewer. Required when the claim touches FDA, HIPAA or advertising rules.
- Approver. The accountable executive who signs off, usually the CMO or a delegate.
- Maintainer. The owner who watches for changes and triggers re-review.
Established publishers show what mature versions look like. OSF HealthCare says its digital health content is built by a mix of clinicians with advanced degrees, medical writers, medical editors, illustrators, multimedia staff and project managers, and that reviewers are mostly independent contractors who are licensed clinicians. Mayo Clinic describes a sequence of editorial research, writing and editing, medical review, copy editing, annotation, visual creation and publishing.
You do not need that headcount. You need the same separation of duties. At a 30-person company, that may mean a marketer drafts, a contracted physician reviews, the fractional CMO approves, and one named person owns the calendar.
Two controls matter more than org charts:
- No self-approval. The person who wrote a claim cannot be the person who clears it.
- Role-based permissions. Healthcare content systems should limit who can edit or publish sensitive material, so only qualified personnel can change medical information.
A review and approval workflow that holds up
A workable workflow has six steps. It is deliberately short.
Step 1: Inventory your claims
List every place clinical claims live: website, product UI, onboarding emails, sales decks, case studies, help center, investor updates, chatbot prompts. Tag each with an owner. Most teams find content they forgot existed.
Step 2: Tier by risk
Not every sentence needs a physician panel. A practical three-tier model:
| Tier | Examples | Review required |
|---|---|---|
| High | Efficacy or outcomes claims, safety statements, diagnostic or treatment language, anything for patients | Clinical plus regulatory review, executive approval |
| Medium | Clinical workflow descriptions, educational blog posts, webinar content | Clinical review, owner approval |
| Low | Company news, event announcements, non-clinical features | Owner approval, spot checks |
A workflow should route specialist review by risk rather than send everything to everyone.
Step 3: Require evidence at submission
The draft arrives with its sources attached: guidelines, consensus statements, peer-reviewed studies, or your own validation data. Mayo's writers draw on guidelines, consensus statements, evidence-based databases and peer-reviewed journals. Your standard can be the same: no source, no claim.
Step 4: Review and block release
The workflow should block release until risk-required specialist and regulatory reviews are complete. A gate that can be skipped under deadline pressure is a suggestion.
Step 5: Freeze the approved version
The version that was reviewed must be the version that ships. Freeze it, store it with its evidence set and the reviewer's decision, and record review and expiry dates.
Step 6: Re-review on a schedule
Medicine changes. OSF says it continuously monitors clinical practice guidelines, association statements, peer-reviewed articles, government publications and research summaries. Set a review cadence by tier: high-risk content more often, low-risk content annually. Content past its date is either renewed, corrected or archived.
Records: what an auditor or acquirer will ask for
Governance you cannot prove does not count. Keep records that answer five questions about any published claim: what it said, what evidence supported it, who reviewed it, when it was approved, and what changed afterward.
Audit records should track the decision path: who changed what, previous and new values, sources, reviewer identity, timestamps and what the approval meant. That last item is often missed. "Approved" can mean "clinically accurate," "legally cleared" or merely "formatted correctly." Define it.
When you correct or retire content, preserve the version and approval history. Mayo posts review and publishing dates on its content and says material may be critically updated or archived. Visible dates build reader trust and force your own team to keep them honest. If you manage retention obligations in software, our data retention plan for compliance officers covers the records side in detail.
U.S. rules your program has to respect
This is not legal advice, and which rules apply depends on what you sell and to whom. Confirm scope with regulatory counsel. The main areas:
FDA advertising and labeling. If your product or a partner's product is a regulated drug, biologic or device, promotional claims fall under FDA rules. For prescription drug advertising, the FDA states that the same statute and regulations apply regardless of the audience the ad targets. In November 2023 the CCN Final Rule required that major side-effect and contraindication statements in direct-to-consumer TV and radio drug ads be clear, conspicuous and neutral. The FDA also finalized guidance on June 27, 2023 on quantitative efficacy and risk information in promotional communications. Pharma-facing healthtech vendors should know these exist because their customers' content approval requirements flow from them.
User-generated content. FDA has indicated it generally does not hold firms responsible for truly independent user-generated content, though corrections a firm chooses to make must meet labeling or advertising requirements. That 2014 webinar guidance is a reason to decide in advance how your team handles corrections.
HIPAA and patient stories. Case studies and testimonials are where healthtech marketing most often drifts into protected health information. HIPAA permits de-identification by expert determination or the Safe Harbor method, which removes specified identifiers and requires no actual knowledge that the person could be identified. HHS also states that covered providers need written authorization from each affected patient before media crews access areas where PHI is visible, which matters for video shoots at customer sites. Build a patient-story checklist into your high-risk tier. For a structured approach to assessment, see our HIPAA risk assessment steps.
A rule of thumb: your governance workflow should ask at intake, "Does this content touch a regulated product, a patient, or a performance claim?" A yes to any of the three moves it into the high tier.
AI-assisted content: the new risk surface
Two AI questions now sit inside content governance.
First, content your team drafts with AI. Treat a generated draft as an unreviewed junior draft. It enters the same tiers, needs the same evidence attachments, and gets the same clinical review. Record that AI was used so reviewers know to check every citation, since fabricated references are a known failure mode.
Second, content that AI systems read and repeat about you. Search assistants and chatbots now summarize company and clinical pages. That makes ownership and freshness more important: a named owner per citable item, dated and approved claim sources, a review cadence, and a route to fix stale or harmful answers. Tools that audit how AI-friendly your content is can help you see what is being surfaced, but the review of clinical accuracy stays with your physician leader.
Third, if you deploy a chat tool inside your product, governance extends to its outputs. Our HIPAA roadmap for ChatGPT deployments covers the privacy side. On the clinical side, the American Medical Association advocates that payment for clinical AI be conditioned on evidence of safety, clinical validation and alignment with familiar clinical decision-making. A sensible internal standard follows the same logic: show validation before you promote a claim.
For tool-level oversight, such as vendor vetting and risk classification, you want a separate AI governance process. Keep the two connected through shared owners and a shared inventory.
Our perspective: where programs fail
We see the same three failure patterns in healthcare SaaS companies.
The claim outruns the evidence. A feature is built, a marketer describes what it might do for outcomes, and nobody asks which study or internal dataset supports the sentence. The fix is cultural as much as procedural: the physician leader has to be in the room before the claim is written, not after the deck is printed.
Review exists, but it is one person. A founder with a clinical background reviews everything, until the company grows and the founder becomes the bottleneck. Or the clinical reviewer is an outside friend with no authority to stop a release. Review without a gate is commentary.
Nobody owns the calendar. Content approved two years ago still sits on the website describing a guideline that changed. No one is responsible for noticing.
Our view is that governance should be as light as the risk allows and as firm as the risk demands. Most startups do not need a committee. They need a tiered workflow, a named clinical approver with real authority, and a spreadsheet or system that shows expiry dates. That is the gap a fractional Chief Medical Officer is built to close: senior clinical judgment embedded in how the company decides what it can say, without a full-time executive salary.
If something in your content process feels misaligned with how your clinical claims are actually supported, I would welcome a conversation.
— Paul Bergeron MD, MBA
A 90-day plan to stand up the program
Days 1 to 30: see what you have.
- Build the claim inventory and assign an owner to each item.
- Identify your top 20 highest-risk claims and check their evidence.
- Name your clinical approver and a backup.
Days 31 to 60: set the rules.
- Adopt the three-tier model and a one-page content standard.
- Create a submission template requiring sources, intended audience and regulated-product flag.
- Define what "approved" means and set expiry dates by tier.
Days 61 to 90: operate and measure.
- Run all new content through the workflow.
- Retire or correct content that fails review.
- Track turnaround time, percentage of content with current review dates, corrections issued and claims found without evidence.
Those four measures tell you whether the program is working. If turnaround climbs, your tiers are too broad. If expired items accumulate, ownership is unclear.
How we help
The StartUp MD is a healthcare advisory firm. We provide Fractional Chief Medical Officer leadership and advisory services to healthcare SaaS and digital health companies, including clinical strategy, regulatory guidance and clinical operations consulting. For content governance, that means a physician leader who sets the standard, approves high-risk claims and builds the workflow with your team, backed by experience in both medicine and business.
See how a Fractional CMO or advisory engagement could work for your company, or start from our home page. Pricing is scoped to your engagement, so reach out for details.
FAQ
Is medical content governance the same as clinical governance?
No. Clinical governance is about accountability for the quality of care an organization delivers. Medical content governance is about the accuracy, evidence and currency of what a company publishes or says about health. They share people, such as a CMO, and some records, but they answer different questions.
Who should approve medical content at a startup?
A licensed clinician with expertise that matches the topic should review it, and an accountable executive should approve it. In many startups that approver is a fractional CMO. Whoever it is needs authority to stop a release, and should not be the person who wrote the content.
How often should medical content be reviewed?
Set the cadence by risk. High-risk content, such as efficacy or safety claims, needs the shortest cycle and a re-review whenever guidelines or product behavior change. Lower-risk content can be reviewed annually. Every item should carry a visible review or expiry date.
Does HIPAA apply to our marketing content?
It can. If a case study, testimonial or video includes protected health information from a covered entity's patients, HIPAA rules on authorization or de-identification apply. Check each patient story against the de-identification methods HHS describes, and ask regulatory counsel about your specific situation.
How should we govern AI-generated content?
Run it through the same tiers and clinical review as human drafts, require verified sources for every claim, and record that AI was used. Keep AI tool oversight in a separate governance process that shares your content inventory and owners.
Sources
- Section 7: Establish Content Governance, ODPHP Health Literacy Online
- AI Governance in Health Systems, Duke-Margolis
- Content Governance in Pharma: Ensuring Compliance
- Digital Health Education Content Development and Sourcing, OSF HealthCare
- Health Information Policy, Mayo Clinic
- How to build a scalable healthcare content strategy, Kontent.ai
- Medical Content Approval Workflow
- How to Build a Medical Content Review and Approval Platform
- OPDP Frequently Asked Questions, FDA
- CCN Final Rule Small Entity Compliance Guide, FDA
- The Brief Summary July 2023, FDA
- Social Media Draft Guidance Webinar Q&As, FDA
- Guidance Regarding Methods for De-identification of PHI, HHS
- Guidance on Covered Health Care Providers and Media Access to PHI, HHS
- H-480.939 Augmented Intelligence in Health Care, AMA